Brief: Expres2ion Biotech Holding Updates On Negotiations With Bavarian Nordic

ExpreS2ion Biotech Holding AB

08/07/2020 14:30

July 8 (Reuters) - ExpreS2ion Biotech Holding AB
 EXPRS2.ST :
    * EXPRES2ION PROVIDES UPDATE ON NEGOTIATIONS WITH BAVARIAN
NORDIC
AND PROGRESS TOWARDS CLINICAL PHASE I/IIA TRIAL
    * ANNOUNCES THAT CVLP COVID-19 VACCINE LICENSE AGREEMENT
NEGOTIATION BETWEEN ITS JOINT VENTURE ADAPTVAC AND BAVARIAN
NORDIC IS EXPECTED TO CONTINUE BEYOND PREVIOUSLY ANNOUNCED TWO
MONTHS' TIME FRAME
    * STILL EXPECTS VACCINE TO ENTER FIRST CLINICAL PHASE I/IIA
SAFETY
TRIAL BEFORE END OF 2020

Source text for Eikon:  ID:nWkr3Hr1Qz 
Further company coverage:  EXPRS2.ST 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))